Michael Patrick Miller - 01 Feb 2026 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Reporting relationship: Director
Issuer ticker: RIGL
Reported as of: 01 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Feb 2026, 16:09:48 UTC
Prior SEC filing: 12 Jan 2026
Next SEC filing: 19 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Raymond Furey (Attorney-in-Fact)

Key filing fact

Michael Patrick Miller filed Form 4 for RIGEL PHARMACEUTICALS INC (RIGL) on 03 Feb 2026.

Key facts

This page summarizes Michael Patrick Miller's Form 4 filing for RIGEL PHARMACEUTICALS INC (RIGL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Feb 2026, 16:09.

Change

Previous filing in this sequence was filed on 12 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001236514 Primary reporting owner

MILLER MICHAEL PATRICK

Relationship: Director
Address: RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO
Signature: /s/ Raymond Furey (Attorney-in-Fact)
Signature date: 03 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RIGL transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +12,000
Change %
Price: $0.000000
Shares after: 12,000
Date: 01 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,000
Exercise price: $34.86
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shall vest in equal monthly installments over a period beginning on February 1, 2026 and ending on the date of the annual meeting at which the Reporting Person is first scheduled to be considered for election by the stockholders, subject to the Reporting Person's continuous service on the Company's Board of Directors.